Drug Development

BenevolentAI becomes first AI company to appoint a Chief Medical Officer

11 January 2017 | By Niamh Marriott (Drug Target Review)

BenevolentAI is the first AI company to have a CMO on its staff.

Kymab receives $9m R+D grant from Bill & Melinda Gates Foundation

9 January 2017 | By Niamh Marriott (Drug Target Review)

The monoclonal antibody biopharmaceutical group Kymab announced today that it has received a $9m grant from the Bill & Melinda Gates Foundation to accelerate the development of novel vaccines and therapeutics for infectious diseases, including HIV.

DiscoverX SAFETYscan™ In Vitro Pharmacological Profiling Services

21 December 2016 | By DiscoverX Corporation

Designed for lead optimisation and safety profiling, DiscoverX’s SAFETYscan in vitro pharmacological profiling services improve off-target liability testing...

Mission Therapeutics appoints Colin Goddard as Chairman

21 December 2016 | By Niamh Marriott (Drug Target Review)

Mission Therapeutics have appointed Dr Colin Goddard as non-executive Chairman, effective January 1st 2017.

Molecular Devices

Versatile applications of next-generation sequencing in pharmaceutics

4 December 2016 | By Pushpanathan Muthuirulan (National Institutes of Health)

Next-generation sequencing (NGS) technologies hold great promise for unravelling the mysteries of biological systems, with the advent of DNA sequencing methods having greatly accelerated biomedical research, gaining broad applicability in disease diagnosis and therapeutics in recent years...

Fine Motor Kinematics in In Vivo Pharmacology

1 December 2016 | By Charles River

This webinar details a novel automated and high-precision system to successfully analyze early changes in muscular or neuronal function in disease models...

Cisbio Bioassays Kinases – A comprehensive platform of assays and reagents for evaluating kinase activity

4 October 2016 | By Cisbio

Cisbio Bioassays has developed several assays for covering all the needs for monitoring kinase targets...

Quotient Clinical expands Data Sciences capability

27 September 2016 | By Quotient Clinical

Department moves into enhanced facility and increases headcount in response to continued demand for services...

Attendee list released for the Orphan Drugs & Rare Diseases 2016

13 September 2016 | By SMi

SMi Reports (13.09. 2016, London, UK): Alexion, BioMarin, Chiesi, MHRA, NICE to meet in London in October to discuss updates in the orphan drug landscape...

Rare Diseases Q&A

16 June 2016 | By Caroline Richards (Drug Target Review)

Releasing colourful balloons into the air to symbolise people who are affected by rare diseases was one of the many ways in which this year’s Rare Disease Day was marked in February. The once-yearly, global campaign aims to raise awareness among the general public and decision-makers about these illnesses and…

Computational methods for drug repositioning

17 February 2016 | By Anaum Rashid (University of Sunderland), Hannah Smith (University of Sunderland), Ken McGarry (University of Sunderland)

Bioinformatics and computational techniques are now experiencing increased attention as a means of improving the costly and time-consuming drug development process...

Human pluripotent stem cell-derived cardiomyocytes in drug discovery and development

12 June 2015 | By Arne Hansen (University Medical Center Hamburg-Eppendorf and DZHK), Boris Greber (Max Planck Institute for Molecular Biomedicine and Chemical Genomics Centre of the Max Planck Society), Dennis Schade (Technical University of Dortmund)

Procedures for cardiac differentiation of human pluripotent stem cells (hPSCs) have greatly improved over the past few years. The facilitated derivation of hPSC-cardiomyocytes has enabled the thorough assessment of their physiology and manipulation of their properties. Moreover, patient-specific hPSCs generated through cellular reprogramming allow for cardiac disease modelling, discovery of…

Sanofi and MyoKardia announce groundbreaking collaboration to develop targeted therapies for patients with genetic heart disease

19 September 2014 | By Sanofi

Sanofi and MyoKardia, Inc. announced a worldwide collaboration to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease...